YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Teva Pharmaceutical Industries Limited (NYSE:TEVA) has agreed to serve as the stalking-horse bidder for substantially all of BioXcel Therapeutics, Inc. (NASDAQ:BTAI)'s assets in a transaction valued at up to $125 million. The deal is struc…
You can be right about the science and still lose every dollar you put in. That is the hardest lesson in small-cap investing, and it shows up in credit agreements and amendment schedules, not in press releases. Here is how the game usually…
Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Limited (NYSE:TEVA), agreed to serve as the stalking-horse bidder for substantially all assets of BioXcel Therapeutics, Inc. (NASDAQ:BTAI) and certain…
Teva Pharmaceutical Industries Limited TEVA announced it has made a bid to acquire certain assets of BioXcel Therapeutics, including the Igalmi (dexmedetomidine) sublingual film. Igalmi, the currently approved formulation of dexmedetomidin…
Teva Pharmaceuticals International has made a bid to acquire a range of neuroscience assets from BioXcel Therapeutics for a total deal value of $125m. The agreement arises as part of BioXcel Therapeutics' voluntary Chapter 11 proceedings i…
Teva Pharmaceuticals International has made a bid to acquire a range of neuroscience assets from BioXcel Therapeutics for a total deal value of $125m. The agreement arises as part of BioXcel Therapeutics' voluntary Chapter 11 proceedings i…
Teva Pharmaceutical Industries (NYSE:TEVA) agreed to acquire BioXcel Therapeutics' dexmedetomidine sublingual film for at-home treatment of agitation in schizophrenia and bipolar disorder through a bankruptcy asset sale process. The transa…
Teva Pharmaceutical Industries stock has delivered a very strong 284.4% gain over the past 5 years, yet current checks send mixed signals as the Discounted Cash Flow (DCF) estimate points to undervaluation while market based multiples scre…
BioXcel Therapeutics (BTAI) has entered into an agreement with Teva Pharmaceutical Industries (TEVA) PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
[Businessman reads Bankruptcy Chapter 11 book.] designer491 * BioXcel Therapeutics (BTAI [https://seekingalpha.com/symbol/BTAI]) filed for Chapter 11 [https://seekingalpha.com/pr/20633273-bioxcel-therapeutics-enters-into-asset-sale-agreeme…
Teva Pharmaceutical Industries Ltd Teva Announces Proposed Acquisition of a Novel Neuroscience Product Reinforcing Disciplined Business Development Approach Under Pivot to Growth StrategyTeva Announces Proposed Acquisition of a Novel Neuro…
BioXcel Therapeutics BioXcel Therapeutics intends to complete a court-supervised sale transaction, in an effort to maximize value for all stakeholders Teva Pharmaceuticals to serve as "stalking horse" bidder in a court-supervised 363 aucti…
BioMarin Pharmaceutical (BMRN) came out with quarterly earnings of $1.2 per share, beating the Zacks Consensus Estimate of $0.96 per share. This compares to earnings of $1.44 per share a year ago. These figures are adjusted for non-recurri…
BioXcel Therapeutics, Inc. (BTAI) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2026. This widely-known consensus outlook gives a good sense of the compa…
We recently compiled a list of the 10 Best Beaten Down Stocks to Invest in According to Analysts. BioXcel Therapeutics, Inc. is one of the best 52-week low stocks. TheFly reported on April 2 that H.C. Wainwright lowered its price target on…
Live event to be held on Thursday, April 23, at 2:00 p.m. ET Company focused on advancing launch strategy ahead of November 14 PDUFA target action date NEW HAVEN, Conn., April 17, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq…
(RTTNews) - BioXcel Therapeutics, Inc. (BTAI) has enrolled the first patients in a U.S. Department of War-funded phase 2a study evaluating BXCL501, its sublingual dexmedtomidine film, for the treatment of acute stress reactions. Acute stre…
DoW-funded Phase 2a trial led by University of North Carolina at Chapel Hill (UNC) Institute for Trauma Recovery Positive outcomes from trial can potentially impact Veteran Affairs/Department of War Clinical Practice Guidelines for managem…
NEW HAVEN, Conn., March 11, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence to develop transformative medicines in neuroscience, today announc…
NEW HAVEN, Conn., March 10, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence to develop transformative medicines in neuroscience, today announc…
(RTTNews) - BioXcel Therapeutics, Inc. (BTAI) said on Tuesday that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration for IGALMI, seeking approval for the acute treatment of agitation assoc…
Penny stocks, especially in the early-stage biotech sector, often tend to be volatile and highly risky, but they also offer the potential for massive rewards. One such company is BioXcel Therapeutics (BTAI), which stands out right now for…
NEW HAVEN, Conn., Jan. 07, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines in neuroscience, today announced that it…
Event Sponsored by BioXcel Therapeutics Set for 10 a.m. EST on Monday, Dec. 8 Topics Covered by Drs. Leslie Citrome, Marc Milano, and Leon Ravin to Include Opportunities and Advantages of Self-Administered Treatments at Home NEW HAVEN, Con…
* BioXcel Therapeutics press release [https://seekingalpha.com/pr/20303392-bioxcel-therapeutics-reports-third-quarter-2025-financial-results-and-provides-update-on-late] (BTAI [https://seekingalpha.com/symbol/BTAI]): Q3 GAAP EPS of -$2.18…
NEW HAVEN, Conn., Oct. 13, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company pioneering the use of artificial intelligence to develop transformative medicines in neuroscience, announced today t…
BioXcel Therapeutics NEW HAVEN, Conn., Oct. 13, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company pioneering the use of artificial intelligence to develop transformative medicines in neuroscien…
* BioXcel Therapeutics (NASDAQ:BTAI [https://seekingalpha.com/symbol/BTAI]) has regained compliance with Nasdaq’s market value of listed securities (MVLS) requirement for continued listing on the exchange. * On March 20, 2025, the company…
NEW HAVEN, Conn., Sept. 18, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that it has…
BXCL501 demonstrated a significant mean reduction in mCGI-S score from baseline compared to placebo at 2 hours across 2,433 treated episodes (p<.05) Complete resolution of agitation was significantly higher with BXCL501 compared to placebo…
Here are the top movers in Wednesday's session, showcasing the stocks with significant price changes. [topmovers] TODAY'S TOP GAINERS TICKER CHANGE COMMENT STSSW [https://www.chartmill.com/stock/quote/STSSW/profile] 86.83% In an impressive…
Intrigued by the market activity in the middle of the day on Wednesday? Uncover the key winners and losers of today's session in our insightful analysis. [topmovers] TODAY'S TOP GAINERS TICKER CHANGE COMMENT STSSW [https://www.chartmill.co…
Let's have a look at what is happening on the US markets on Wednesday. Below you can find the gap up and gap down stocks in today's session. [gap] TODAY'S GAP UP STOCKS TICKER CHANGE COMMENT NBY [https://www.chartmill.com/stock/quote/NBY/p…
[Arrows up & down] Oakozhan/iStock via Getty Images Shares of BioXcel Therapeutics (NASDAQ:BTAI [https://seekingalpha.com/symbol/BTAI]) initially climbed and then fell in the premarket on Wednesday after the New Haven, Connecticut-based bi…
BXCL501 achieved SERENITY At-Home’s primary endpoint of being well tolerated in the at-home treatment of agitation episodes in patients with bipolar disorders or schizophrenia No discontinuations for tolerability in the BXCL501 arm While n…